CYP1B1 Val genotype is associated with lower response rate, shorter progression-free-survival and decrease overall survival in breast and prostate cancer patients treated with taxanes based chemotherapy (Marsh et al. 2007; Sissung et al. 2008; Pastina et al. 2010). The gene discussed is CYP1B1; the disease is prostate carcinoma.